Intercept Pharmaceuticals Inc
NASDAQ:ICPT
Intrinsic Value
Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. [ Read More ]
The intrinsic value of one ICPT stock under the Base Case scenario is 22.75 USD. Compared to the current market price of 19 USD, Intercept Pharmaceuticals Inc is Undervalued by 16%.
Valuation Backtest
Intercept Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling ICPT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Intercept Pharmaceuticals Inc's business.
What risks and challenges
does Intercept Pharmaceuticals Inc face in the near future?
Summarize the latest earnings report
of Intercept Pharmaceuticals Inc.
Provide P/E
for Intercept Pharmaceuticals Inc and its competitors.
Balance Sheet Decomposition
Intercept Pharmaceuticals Inc
Current Assets | 383.4m |
Cash & Short-Term Investments | 322.7m |
Receivables | 32.5m |
Other Current Assets | 28.3m |
Non-Current Assets | 9.7m |
PP&E | 5.8m |
Other Non-Current Assets | 3.9m |
Current Liabilities | 90.8m |
Accounts Payable | 10.3m |
Accrued Liabilities | 39m |
Other Current Liabilities | 41.6m |
Non-Current Liabilities | 230.5m |
Long-Term Debt | 223.9m |
Other Non-Current Liabilities | 6.6m |
Earnings Waterfall
Intercept Pharmaceuticals Inc
Revenue
|
317.7m
USD
|
Cost of Revenue
|
-632k
USD
|
Gross Profit
|
317.1m
USD
|
Operating Expenses
|
-372.1m
USD
|
Operating Income
|
-55.1m
USD
|
Other Expenses
|
-6.5m
USD
|
Net Income
|
-61.6m
USD
|
Free Cash Flow Analysis
Intercept Pharmaceuticals Inc
What is Free Cash Flow?
ICPT Profitability Score
Profitability Due Diligence
Intercept Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Intercept Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
ICPT Solvency Score
Solvency Due Diligence
Intercept Pharmaceuticals Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Intercept Pharmaceuticals Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ICPT Price Targets Summary
Intercept Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ICPT is 19 USD .
Ownership
ICPT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ICPT Price
Intercept Pharmaceuticals Inc
Average Annual Return | -36.19% |
Standard Deviation of Annual Returns | 41.53% |
Max Drawdown | -93% |
Market Capitalization | 794.4m USD |
Shares Outstanding | 41 826 000 |
Percentage of Shares Shorted | 25.19% |
ICPT News
Last Important Events
Intercept Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Intercept Pharmaceuticals Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 437 full-time employees. The company went IPO on 2012-10-11. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The firm is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. The Company’s other compounds are in early stages of research and development pipeline, including INT-787 compound, an FXR agonist is in a Phase I clinical trial.
Contact
IPO
Employees
Officers
The intrinsic value of one ICPT stock under the Base Case scenario is 22.75 USD.
Compared to the current market price of 19 USD, Intercept Pharmaceuticals Inc is Undervalued by 16%.